Trials / Recruiting
RecruitingNCT06598046
A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC
A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of Triple-negative Advanced Breast Cancer.
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to explore the efficacy and safety of the combination therapy of utidelone and capecitabine in the treatment of brain metastases from triple-negative advanced breast cancer, and to search for systemic treatment for brain metastases from triple-negative advanced breast cancer cases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Utidelone and capecitabine | Utidelone: intravenous capecitabine: oral |
Timeline
- Start date
- 2024-06-19
- Primary completion
- 2026-06-01
- Completion
- 2026-08-01
- First posted
- 2024-09-19
- Last updated
- 2024-09-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06598046. Inclusion in this directory is not an endorsement.